Navigation Links
NeoStrata(R) Announces the Launch of PSORENT(TM) Psoriasis Topical Treatment

PSORENT Features a Unique and Innovative Formulation Available Without a

Prescription Through Physicians

PRINCETON, N.J., Feb. 4 /PRNewswire/ -- NeoStrata today announced the launch of PSORENT, a clinically proven, steroid-free, topical treatment for psoriasis. PSORENT contains LCD (liquid carbonis distillate), which has proven efficacy against psoriasis symptoms, in a novel, aesthetically advanced formulation and package that promotes high patient compliance. PSORENT is available without a prescription from dermatologists beginning March 2008.

"With the launch of PSORENT, physicians will be able to offer patients a novel psoriasis treatment that reduces the unpleasant aspects of traditional coal tar therapy, resulting in high patient compliance without compromising efficacy or safety," said Barbara Green, Vice President for Technology and Clinical Affairs at NeoStrata. "PSORENT's effective and unique fast-absorbing solution applies easily and conveniently making it an ideal first-line therapy for the vast majority of psoriasis patients."

PSORENT is an aesthetically advanced, fast absorbing topical coal tar solution that provides a new alternative for psoriasis patients and providers. Optimally formulated with a 15 percent concentration of LCD, the therapeutic equivalent of 2.3 percent coal tar, PSORENT is an innovative topical solution to treat the chronic redness and scaling associated with psoriasis. PSORENT is supplied in a convenient dab-on delivery system that speeds LCD absorption and avoids the stains, odor and mess that are typically associated with coal tar treatments. Additionally, the dab-on applicator allows the patient to apply PSORENT directly to the affected areas without touching either the solution or the skin, resulting in a highly effective and easy to use treatment. PSORENT is available only through physicians' offices. One 100mL bottle provides up to a 3-month supply, at a suggested retail price of $45.00, making it a cost effective alternative to prescription medications which may or may not be covered by health insurance.

Psoriasis is an immune-mediated, genetic disease manifesting in the skin and/or the joints. According to the National Institutes of Health, as many as 7.5 million Americans have psoriasis. The National Psoriasis Foundation defines mild psoriasis as affecting less than three percent of the body; three percent to 10 percent is considered moderate; more than 10 percent is considered severe. According to the National Psoriasis Foundation's Benchmark Survey on Psoriasis and Psoriatic Arthritis, the disease is not merely a cosmetic problem. Nearly 60 percent reported their psoriasis to be a large problem in their everyday life. The survey also indicates that psoriasis had a greater impact on quality of life in women and younger patients.

About NeoStrata

The NeoStrata Company, located in Princeton, NJ, develops and markets advanced therapeutic and cosmetic dermatological products through consumer outlets and physicians' offices in the United States and internationally through physicians' offices, pharmacies and spas.

SOURCE The NeoStrata Company
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
4. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
5. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
6. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
11. CNS Response Announces Fiscal Third Quarter 2007 Results
Post Your Comments:
(Date:10/13/2015)... , October 13, 2015 the United ... Europe .  PRCC represents about 14% of all new cases ... , Canada and Europe ... kidney cancer.   --> Hutchison China MediTech Limited ("Chi-Med") ... R&D subsidiary, and AstraZeneca AB (publ) ("AstraZeneca") have completed enrolment in ...
(Date:10/12/2015)... Oct.12, 2015  MiMedx Group, Inc. (NASDAQ: MDXG ... tissue and patent-protected processes to develop and market advanced ... Spine, Sports Medicine, Ophthalmic, and the Dental sectors of ... been filed against the Company has been dismissed by ... Chairman and CEO, stated, "As we suspected, this case ...
(Date:10/12/2015)... 2015 cell surface marker detection market ... according to a new report by Grand View Research, Inc. ... incidence of oncology diseases and other cell-associated disorders. --> ... reach USD 6.49 billion by 2022, according to a new ... can be attributed to rise in incidence of oncology diseases ...
(Date:10/12/2015)... DIEGO , Oct. 12, 2015  Patara ... debilitating allergic and inflammatory diseases and conditions, today ... A preferred stock financing. Concurrent with the close ... entered into a Loan and Security Agreement with ... up to $7 million. Patara will use the ...
Breaking Biology Technology:
(Date:9/29/2015)... , Sept. 29, 2015 ... employee productivity while also saving energy , Minimized ... as Low Power Active Mode and embedded Fujitsu PalmSecure ... Fujitsu today shows that good things ... and refreshed models to its enterprise desktop and mobile ...
(Date:9/28/2015)... YORK , Sept. 28, 2015 /PRNewswire/ ... announced today that its expedited traveler service ... innovative platform transforms travel, bringing a frictionless ... its members. "CLEAR offers our ... enhances customer service," said Jim Smith ...
(Date:9/28/2015)... SAN FRANCISCO , September 28, 2015 ... size is expected to reach USD 12.03 billion by ... to 2020. Technological advancements such as Backside Illumination (BSI) ... revenue growth over the forecast period.      ... the back of the chip to reduce loss and, ...
Breaking Biology News(10 mins):